Bicara Therapeutics Inc. Common Stock
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody with a domain that binds to human transforming growth factor beta for the treatment of solid tumor… Read more
Market Cap & Net Worth: Bicara Therapeutics Inc. Common Stock (BCAX)
Bicara Therapeutics Inc. Common Stock (NASDAQ:BCAX) has a market capitalization of $1.25 Billion ($1.25 Billion) as of March 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #8859 globally and #4387 in its home market, demonstrating a -1.93% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Bicara Therapeutics Inc. Common Stock's stock price $19.32 by its total outstanding shares 64797727 (64.80 Million).
Bicara Therapeutics Inc. Common Stock Market Cap History: 2024 to 2026
Bicara Therapeutics Inc. Common Stock's market capitalization history from 2024 to 2026. Data shows growth from $1.13 Billion to $1.25 Billion (4.80% CAGR).
Index Memberships
Bicara Therapeutics Inc. Common Stock is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.24 Trillion | 0.03% | #249 of 976 |
|
NASDAQ Composite
IXIC
|
$33.39 Trillion | 0.00% | #951 of 3165 |
Weight: Bicara Therapeutics Inc. Common Stock's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Bicara Therapeutics Inc. Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Bicara Therapeutics Inc. Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of BCAX by Market Capitalization
Companies near Bicara Therapeutics Inc. Common Stock in the global market cap rankings as of March 18, 2026.
Key companies related to Bicara Therapeutics Inc. Common Stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Bicara Therapeutics Inc. Common Stock Historical Marketcap From 2024 to 2026
Between 2024 and today, Bicara Therapeutics Inc. Common Stock's market cap moved from $1.13 Billion to $ 1.25 Billion, with a yearly change of 4.80%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.25 Billion | +14.80% |
| 2025 | $1.09 Billion | -3.39% |
| 2024 | $1.13 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Bicara Therapeutics Inc. Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.25 Billion USD |
| MoneyControl | $1.25 Billion USD |
| MarketWatch | $1.25 Billion USD |
| marketcap.company | $1.25 Billion USD |
| Reuters | $1.25 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.